New Approach to Diagnosing High-Risk, Early-Stage Ovarian Cancer

OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

Swedish researchers have, for the first time, used a combination of methods to accurately diagnose high-risk patents with early-stage ovarian cancer, thereby identifying those who would benefit from more aggressive treatment.

Swedish researchers have, for the first time, used a combinationof methods to accurately diagnose high-risk patents with early-stageovarian cancer, thereby identifying those who would benefit frommore aggressive treatment.

Historically, physicians have had difficulties in identifyinghigh-risk patients from among women with early-stage ovarian cancer.Overall, 75% of these patients survive, but about 25% will stilldie from the disease. Patients with a poor prognosis can be treatedwith chemotherapy and radiation therapy.

The results of the study were presented by Dr. Nina Einhorn ofthe Department of Gynecological Oncology, Karolinska Institute,Stockholm, Sweden, at the American Radium Society's annual meeting,held in Paris. Based on a 10-year follow-up of 95 ovarian cancerpatients treated for early stages of the disease, Dr. Einhornand colleagues found that by using a combination of biologic,morphologic, and clinical methods they could accurately determinewhether such patients would benefit from aggressive treatment.

The biologic methods included image DNA analysis and the examinationof cell growth activity and gene products that are involved incell growth, such as tumor-suppressor gene p53 and the Waf-1 gene.Genetic instability, as reflected by DNA aneuploidy, extensivecell growth, and mutation of the p53 gene, indicated a high-riskpatient. Aggressive treatment is probably the only way to savethese patients' lives, according to Dr. Einhorn.

"We believe that by using this combination of methods wehave developed the most accurate and useful way to see if thecancer needs to be treated," she said. "What we havedone is simply to find a new way to look at the diagnostic problem.If we have a better way to diagnose these early cases, we canbetter treat them."

Other Karolinska investigators who took part in the study wereDrs. Gert Auer, Claes Silfversward, and Kerstin Sjovall of thedepartments of gynecology, pathology,and gynecological oncology.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.